Over the past 22 months, testing has been the first line of defence against the global battle with COVID-19. Thanks to Doctor Todd Hatchette, Service Chief for Microbiology and his laboratory team, Nova Scotia has been recognized around the world for our testing response, policies, access, and public promotion in our combat against the virus.
Nova Scotia Health’s Mental Health Day Treatment team has relocated from the Abbie J. Lane Building site of the QEII Health Sciences Centre to the Marshall Treatment Centre on the Nova Scotia Hospital site to make space for the new mental health acute day hospital.
In an effort to ensure all Nova Scotians have access to COVID-19 testing, especially those in rural communities where testing is not available nearby, the Public Health mobile units will be offering testing in various communities across the province.
From the time she was born, Joanne Rose has been battling an inherited disorder that has impacted the health of her kidneys.
Polycystic kidney disease (PKD) is a congenital illness in which clusters of cysts develop primarily within the kidneys, causing them to enlarge and lose function over time. For Rose, she didn’t know she had the illness, or that her kidneys were losing function until 1980, at the age of 21.
From aging laboratory equipment to creating revenue in health care, Randy Veinotte, esoteric laboratory manager at Nova Scotia Health played a pivotal role in generating revenue to re-invest in the province’s health care system.
I am Tasha Ramsey, an infectious diseases pharmacist and co-chair of the COVID-19 Therapeutics and Prophylactics Advisory Group.
This advisory group reviews the evidence for COVID-19 medications and makes recommendations for their use in Nova Scotia.
While people are still testing positive for COVID-19, I hear Nova Scotians have questions about nirmatrelvir/ritonavir, also known as Paxlovid – a medication that may be used to treat people with COVID-19.